Nearly 70% of men with locally recurrent prostate cancer who received radiation therapy initially could delay androgen deprivation therapy (ADT) for at least five years following stereotactic body radiation therapy (SBRT) with Accuray Inc.’s Cyberknife system, according to a study published in the International Journal of Radiation Oncology • Biology • Physics.